Welcome to our dedicated page for Neuronetics news (Ticker: STIM), a resource for investors and traders seeking the latest updates and insights on Neuronetics stock.
Overview
Neuronetics Inc. (NASDAQ: STIM) is a commercial stage medical technology company that focuses on designing, developing and marketing innovative, noninvasive treatments for mental health and neurohealth disorders. At the heart of its portfolio is the NeuroStar Advanced Therapy System, a revolutionary transcranial magnetic stimulation (TMS) platform that utilizes MRI-strength magnetic field pulses to stimulate targeted regions in the brain. This technology is engineered to serve patients with major depressive disorder (MDD) and other psychiatric conditions, particularly for those who have not experienced satisfactory results with traditional pharmaceutical treatments.
Core Technology and Treatment Modality
Neuronetics has established its reputation by pioneering non-drug, noninvasive therapeutic solutions that redefine patient care in the mental health space. The NeuroStar Advanced Therapy System, cleared by the FDA, is designed to generate pulsed magnetic fields to induce controlled electrical currents in focus areas of the brain. This precise approach not only offers an alternative to systemic medications but also addresses the limitations of conventional treatment methods. The company’s emphasis on robust clinical data and the world’s largest depression outcomes registry reinforces its position as an authority in TMS therapy.
Business Model and Operational Focus
The primary revenue streams for Neuronetics are derived from sales of its NeuroStar system and the associated treatment sessions delivered in a clinical setting. Additionally, the company supports a network of treatment centers that provide these services, thereby integrating technology with operational excellence in patient care. By providing comprehensive clinical training and standardizing best practices through initiatives like its Better Me Provider program, Neuronetics ensures consistent treatment quality. Its business strategy is underpinned by a commitment to continuously engage with payors, healthcare providers and policy makers to expand access to TMS therapy.
Market Position and Competitive Differentiation
Neuronetics occupies a distinct niche in the growing field of neurostimulation devices. Its status as the first company to obtain FDA clearance for a noninvasive TMS device specifically indicated for patients who have not benefited from previous antidepressant medications sets it apart in a competitive market. The company’s dedication to research-driven innovation, combined with its extensive clinical adoption, reinforces its credibility among medical professionals and investors alike. Furthermore, recent strategic mergers have enhanced its operational scale, creating a vertically integrated organization that fosters consistent delivery of standardized best practices across treatment sites.
Clinical Impact and Research Excellence
At the core of Neuronetics’ approach is a commitment to improving patient outcomes. Its NeuroStar Advanced Therapy System has been validated by a significant clinical data set, establishing strong response and remission rates among patients with MDD. The system is also cleared for use in adolescent populations, addressing the critical need for early intervention in mental health care. Neuronetics continues to invest in research and development to assess the full spectrum of benefits associated with TMS therapy, thereby deepening the clinical understanding of treatment efficacy and safety.
Industry Expertise and Authoritativeness
With a dedicated team specialized in health policy advocacy and clinical education, Neuronetics bridges the gap between innovative technology and evidence-based mental health care. The firm’s ability to collaborate with both commercial and government payors to expand insurance coverage for TMS treatments showcases its expertise and strategic foresight. Its work is consistently informed by high-quality clinical research and real-world evidence, making it a trusted source of innovative mental health solutions.
Summary
In summary, Neuronetics stands out in the medical device industry by combining cutting-edge TMS technology with a patient-centric approach to mental health care. Its NeuroStar Advanced Therapy System offers a noninvasive, clinical alternative for those with depression and anxiety, backed by extensive clinical validation. Through its integrated network of treatment centers, robust clinical data and strategic collaborations, Neuronetics reinforces its authority in the neurostimulation space and continues to shape the landscape of mental health treatment.
Neuronetics (NASDAQ: STIM) announced that Evernorth Health Services, a Cigna subsidiary, has expanded coverage of NeuroStar® Transcranial Magnetic Stimulation (TMS) to include adolescents aged 15 and older with major depressive disorder (MDD). This expansion, effective immediately, impacts 15 million covered lives.
The coverage update follows NeuroStar's FDA clearance as the first first-line add-on treatment for adolescents aged 15-21 with MDD. Several major insurers, including Humana, Aetna, and Medi-Cal, have updated their policies in response to this clearance.
The expansion addresses a significant need, as approximately 4.3 million U.S. adolescents aged 15-21 are affected by major depression. NeuroStar TMS offers a non-drug treatment option that can be used as a first-line add-on therapy with proven clinical outcomes.
Neuronetics (NASDAQ: STIM) has issued updated financial results for Q4 and full year 2024, revising figures initially reported on March 4, 2025. The revisions, related to the Greenbrook TMS acquisition, include:
For Q4 2024: Operating expenses increased to $26.4M from $25.8M, net loss widened to $(12.7M) from $(12.2M), loss per share increased to $(0.34) from $(0.33), and adjusted EBITDA decreased to $(0.4M) from $0.1M.
For Full Year 2024: Operating expenses rose to $88.7M from $88.2M, net loss expanded to $(43.7M) from $(43.2M), loss per share increased to $(1.38) from $(1.37), and adjusted EBITDA declined to $(21.8M) from $(21.3M).
Neuronetics (NASDAQ: STIM) reported its Q4 and full-year 2024 financial results, highlighting significant strategic developments. The company completed the acquisition of Greenbrook TMS on December 9, 2024, and secured $10 million in additional funding from Perceptive Advisors.
Q4 2024 revenue reached $22.5 million, up 11% year-over-year, with U.S. NeuroStar system revenue at $3.8 million and treatment session revenue at $12.9 million. Full-year 2024 revenue was $74.9 million, a 5% increase from 2023.
The company reported a Q4 net loss of $(12.2) million and a full-year net loss of $(43.2) million. In February 2025, Neuronetics completed a secondary offering raising $18.9 million. The company has executed actions to realize over $21 million of the targeted $22 million in annual cost synergies related to the Greenbrook acquisition.
Looking ahead, Neuronetics projects Q1 2025 revenue between $28-30 million and full-year 2025 revenue of $145-155 million. The company expects to achieve cash flow positivity by Q3 2025.
Neuronetics (NASDAQ: STIM) has announced the granting of inducement awards consisting of Restricted Stock Units (RSUs) representing 24,750 shares of common stock to three new non-executive employees. The awards were approved by the company's Compensation Committee in compliance with NASDAQ Listing Rule 5635(c)(4).
The RSU grants have different vesting schedules: three grants will vest in equal installments over three years on the first, second, and third anniversaries of the grant date, while one grant will vest over four years on the second, third, and fourth anniversaries. All grants are contingent upon continued employment with the company through the vesting dates and are subject to the Neuronetics 2020 Inducement Plan terms.
Neuronetics (NASDAQ: STIM), a medical technology company specializing in neurohealth disorders treatment solutions, has announced it will release its fourth quarter 2024 financial and operating results before the market opens on Tuesday, March 4, 2025.
The company will host a conference call to discuss the results at 8:30 a.m. Eastern Time on the same day. Investors can access the live webcast in listen-only mode, and telephone participants are encouraged to register and join 10 minutes before the event start.
Neuronetics (NASDAQ: STIM) has announced the granting of inducement awards consisting of Restricted Stock Units (RSUs) representing 15,750 shares of common stock to two new non-executive employees. The awards, approved by the company's Compensation Committee under NASDAQ Listing Rule 5635(c)(4), serve as material inducements for employment. These RSUs will vest in equal installments over three years on the first, second, and third anniversaries of the grant date, contingent on continued employment. The awards are governed by the Neuronetics 2020 Inducement Plan.
Neuronetics (NASDAQ: STIM) has priced its previously announced underwritten public offering of 8,000,000 shares of common stock at $2.25 per share, expecting to raise approximately $18 million in gross proceeds before deducting expenses. The company has granted underwriters a 30-day option to purchase up to an additional 1,200,000 shares.
The offering is expected to close around February 10, 2025. Canaccord Genuity is acting as sole bookrunner. The net proceeds will be used for general corporate purposes, including sales and marketing, R&D activities, potential acquisitions, inventory purchases, administrative matters, working capital, and capital expenditures.
Neuronetics (NASDAQ: STIM) has announced the launch of an underwritten public offering of its common stock. The company plans to grant the underwriter, Canaccord Genuity , a 30-day option to purchase up to an additional 15% of the shares offered in the public offering. All shares will be offered by the company.
The offering will be conducted under a shelf registration statement previously filed with the SEC on November 9, 2022, and declared effective on November 14, 2022. The final terms, size, and completion of the offering are subject to market conditions and there is no guarantee of completion.
Neuronetics (NASDAQ: STIM) has announced two peer-reviewed publications in the inaugural edition of the Transcranial Magnetic Stimulation journal, highlighting significant findings about TMS therapy for depression. The first publication demonstrates that transcranial magnetic stimulation (TMS) produces universal improvement in depressive symptoms. The second study reveals that the Patient Health Questionnaire-9 (PHQ-9) shows greater sensitivity compared to the Quick Inventory of Depressive Symptomatology: Self-Report (QIDS-SR) in measuring TMS outcomes.
These publications aim to advance mental health treatment through research and provide clinicians with better tools for patient care. According to Keith J. Sullivan, President and CEO, these findings reinforce TMS's effectiveness in treating depression symptoms while offering insights for more precise clinical care.
Neuronetics (NASDAQ: STIM) announced its preliminary unaudited 2024 financial results and issued 2025 guidance. For 2024, the company reported fourth-quarter revenue of $22.1 million and full-year revenue of $74.5 million. The acquisition of Greenbrook TMS was completed on December 9, 2024, contributing to these figures. The pro forma revenue for Q4 2024 was $34.7 million, while for the full year, it was $129.8 million.
Neuronetics expects 2025 revenue to grow by 12%-19%, reaching between $145 million and $155 million. The company also anticipates achieving over $22 million in annualized cost synergies and aims to be cash flow positive by Q3 2025. Key highlights include the successful integration of Greenbrook TMS, the launch of the Better Me Provider program, and FDA clearance for NeuroStar Advanced Therapy as a first-line add-on treatment for adolescents with depression.
The Better Me Provider program, launched in July 2024, has shown significant improvements in patient care and accessibility. Additionally, the FDA clearance in March 2024 expanded the addressable market for Neuronetics' NeuroStar TMS Therapy by 35%, targeting adolescents aged 15-21 with major depressive disorder.
FAQ
What is the current stock price of Neuronetics (STIM)?
What is the market cap of Neuronetics (STIM)?
What does Neuronetics Inc. specialize in?
How does the NeuroStar Advanced Therapy System work?
What makes Neuronetics different from other medical device companies?
Who are the primary patients for NeuroStar therapy?
How does Neuronetics generate revenue?
What role does clinical research play in Neuronetics' strategy?
How does Neuronetics collaborate with healthcare providers?
